Cargando…

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?

Myelodysplastic syndrome (MDS) represents a heterogeneous group of diseases with clonal proliferation, bone marrow failure and increasing risk of transformation into an acute myeloid leukaemia. Structured guidelines are developed for selective therapy based on prognostic subgroups, age, and performa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stintzing, Sebastian, Kemmerling, Ralf, Kiesslich, Tobias, Alinger, Beate, Ocker, Matthias, Neureiter, Daniel
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100562/ https://www.ncbi.nlm.nih.gov/pubmed/21629744 http://dx.doi.org/10.1155/2011/214143

Ejemplares similares

Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future
por: Ocker, Matthias, et al.
Publicado: (2021)

Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
por: Neureiter, Daniel, et al.
Publicado: (2019)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
por: Zopf, Steffen, et al.
Publicado: (2012)

Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation
por: Bekric, Dino, et al.
Publicado: (2022)

Influence of Five Potential Anticancer Drugs on Wnt Pathway and Cell Survival in Human Biliary Tract Cancer Cells
por: WACHTER, Julia, et al.
Publicado: (2011)

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
por: Di Fazio, Pietro, et al.
Publicado: (2010)

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
por: Ellinghaus, Peter, et al.
Publicado: (2022)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer
por: Di Fazio, Pietro, et al.
Publicado: (2016)

Biliary tract cancer stem cells - translational options and challenges
por: Mayr, Christian, et al.
Publicado: (2017)

Low VDAC1 Expression Is Associated with an Aggressive Phenotype and Reduced Overall Patient Survival in Cholangiocellular Carcinoma
por: Feichtinger, René Günther, et al.
Publicado: (2019)

Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma
por: Bekric, Dino, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone acetylation and the role of histone deacetylases in normal cyclic endometrium
por: Gujral, Palak, et al.
Publicado: (2020)

Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors
por: KEMMERLING, RALF, et al.
Publicado: (2014)

Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis
por: Neureiter, Daniel, et al.
Publicado: (2008)

The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications
por: Klieser, Eckhard, et al.
Publicado: (2019)

Genome-scale network model of metabolism and histone acetylation reveals metabolic dependencies of histone deacetylase inhibitors
por: Shen, Fangzhou, et al.
Publicado: (2019)

Histone deacetylase 3 indirectly modulates tubulin acetylation
por: Bacon, Travis, et al.
Publicado: (2015)

The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells
por: Mayr, Christian, et al.
Publicado: (2015)

Histone deacetylases control lysine acetylation of ribosomal proteins in rice
por: Xu, Qiutao, et al.
Publicado: (2021)

Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy
por: Sun, Xin, et al.
Publicado: (2022)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Dysferlin Interacts with Histone Deacetylase 6 and Increases alpha-Tubulin Acetylation
por: Di Fulvio, Sabrina, et al.
Publicado: (2011)

Can We Efficiently Target HDAC in Cancer?
por: Kiesslich, Tobias, et al.
Publicado: (2022)

Histone Acetylation Level and Histone Acetyltransferase/Deacetylase Activity in Ejaculated Sperm from Normozoospermic Men
por: Kim, Jee Hyun, et al.
Publicado: (2014)

Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo
por: Kelly, R. D. W., et al.
Publicado: (2018)

Methylation-directed acetylation of histone H3 regulates developmental sensitivity to histone deacetylase inhibition
por: Huang, Li-Yao, et al.
Publicado: (2021)

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
por: Tien Anh, Duong, et al.
Publicado: (2023)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Repression of the PRELP gene is relieved by histone deacetylase inhibitors through acetylation of histone H2B lysine 5 in bladder cancer
por: Shozu, Kanto, et al.
Publicado: (2022)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Histone Deacetylase Inhibitors Globally Enhance H3/H4 Tail Acetylation Without Affecting H3 Lysine 56 Acetylation
por: Drogaris, Paul, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qnh4bcaoundjbmju1jcivd3int